BACKGROUND: False-positive mammography results are common. Biennial screening may decrease the cumulative probability of false-positive results across many years of repeated screening but could also delay cancer diagnosis. OBJECTIVE: To compare the cumulative probability of false-positive results and the stage distribution of incident breast cancer after 10 years of annual or biennial screening mammography. DESIGN: Prospective cohort study. SETTING: 7 mammography registries in the National Cancer Institute-funded Breast Cancer Surveillance Consortium. PARTICIPANTS: 169,456 women who underwent first screening mammography at age 40 to 59 years between 1994 and 2006 and 4492 women with incident invasive breast cancer diagnosed between 1996 and 2006. MEASUREMENTS: False-positive recalls and biopsy recommendations stage distribution of incident breast cancer. RESULTS: False-positive recall probability was 16.3% at first and 9.6% at subsequent mammography. Probability of false-positive biopsy recommendation was 2.5% at first and 1.0% at subsequent examinations. Availability of comparison mammograms halved the odds of a false-positive recall (adjusted odds ratio, 0.50 [95% CI, 0.45 to 0.56]). When screening began at age 40 years, the cumulative probability of a woman receiving at least 1 false-positive recall after 10 years was 61.3% (CI, 59.4% to 63.1%) with annual and 41.6% (CI, 40.6% to 42.5%) with biennial screening. Cumulative probability of false-positive biopsy recommendation was 7.0% (CI, 6.1% to 7.8%) with annual and 4.8% (CI, 4.4% to 5.2%) with biennial screening. Estimates were similar when screening began at age 50 years. A non-statistically significant increase in the proportion of late-stage cancers was observed with biennial compared with annual screening (absolute increases, 3.3 percentage points [CI, -1.1 to 7.8 percentage points] for women age 40 to 49 years and 2.3 percentage points [CI, -1.0 to 5.7 percentage points] for women age 50 to 59 years) among women with incident breast cancer. LIMITATIONS: Few women underwent screening over the entire 10-year period. Radiologist characteristics influence recall rates and were unavailable. Most mammograms were film rather than digital. Incident cancer was analyzed in a small sample of women who developed cancer. CONCLUSION: After 10 years of annual screening, more than half of women will receive at least 1 false-positive recall, and 7% to 9% will receive a false-positive biopsy recommendation. Biennial screening appears to reduce the cumulative probability of false-positive results after 10 years but may be associated with a small absolute increase in the probability of late-stage cancer diagnosis. PRIMARY FUNDING SOURCE: National Cancer Institute.
BACKGROUND: False-positive mammography results are common. Biennial screening may decrease the cumulative probability of false-positive results across many years of repeated screening but could also delay cancer diagnosis. OBJECTIVE: To compare the cumulative probability of false-positive results and the stage distribution of incident breast cancer after 10 years of annual or biennial screening mammography. DESIGN: Prospective cohort study. SETTING: 7 mammography registries in the National Cancer Institute-funded Breast Cancer Surveillance Consortium. PARTICIPANTS: 169,456 women who underwent first screening mammography at age 40 to 59 years between 1994 and 2006 and 4492 women with incident invasive breast cancer diagnosed between 1996 and 2006. MEASUREMENTS: False-positive recalls and biopsy recommendations stage distribution of incident breast cancer. RESULTS: False-positive recall probability was 16.3% at first and 9.6% at subsequent mammography. Probability of false-positive biopsy recommendation was 2.5% at first and 1.0% at subsequent examinations. Availability of comparison mammograms halved the odds of a false-positive recall (adjusted odds ratio, 0.50 [95% CI, 0.45 to 0.56]). When screening began at age 40 years, the cumulative probability of a woman receiving at least 1 false-positive recall after 10 years was 61.3% (CI, 59.4% to 63.1%) with annual and 41.6% (CI, 40.6% to 42.5%) with biennial screening. Cumulative probability of false-positive biopsy recommendation was 7.0% (CI, 6.1% to 7.8%) with annual and 4.8% (CI, 4.4% to 5.2%) with biennial screening. Estimates were similar when screening began at age 50 years. A non-statistically significant increase in the proportion of late-stage cancers was observed with biennial compared with annual screening (absolute increases, 3.3 percentage points [CI, -1.1 to 7.8 percentage points] for women age 40 to 49 years and 2.3 percentage points [CI, -1.0 to 5.7 percentage points] for women age 50 to 59 years) among women with incident breast cancer. LIMITATIONS: Few women underwent screening over the entire 10-year period. Radiologist characteristics influence recall rates and were unavailable. Most mammograms were film rather than digital. Incident cancer was analyzed in a small sample of women who developed cancer. CONCLUSION: After 10 years of annual screening, more than half of women will receive at least 1 false-positive recall, and 7% to 9% will receive a false-positive biopsy recommendation. Biennial screening appears to reduce the cumulative probability of false-positive results after 10 years but may be associated with a small absolute increase in the probability of late-stage cancer diagnosis. PRIMARY FUNDING SOURCE: National Cancer Institute.
Authors: L Tabár; B Vitak; H H Chen; S W Duffy; M F Yen; C F Chiang; U B Krusemo; T Tot; R A Smith Journal: Radiol Clin North Am Date: 2000-07 Impact factor: 2.303
Authors: Laura E Ichikawa; William E Barlow; Melissa L Anderson; Stephen H Taplin; Berta M Geller; R James Brenner Journal: Radiology Date: 2010-05-26 Impact factor: 11.105
Authors: K Kerlikowske; P A Carney; B Geller; M T Mandelson; S H Taplin; K Malvin; V Ernster; N Urban; G Cutter; R Rosenberg; R Ballard-Barbash Journal: Ann Intern Med Date: 2000-12-05 Impact factor: 25.391
Authors: Lennarth Nyström; Ingvar Andersson; Nils Bjurstam; Jan Frisell; Bo Nordenskjöld; Lars Erik Rutqvist Journal: Lancet Date: 2002-03-16 Impact factor: 79.321
Authors: Stephen H Taplin; L Abraham; B M Geller; B C Yankaskas; D S M Buist; R Smith-Bindman; C Lehman; D Weaver; P A Carney; W E Barlow Journal: J Natl Cancer Inst Date: 2010-07-02 Impact factor: 13.506
Authors: C L Christiansen; F Wang; M B Barton; W Kreuter; J G Elmore; A E Gelfand; S W Fletcher Journal: J Natl Cancer Inst Date: 2000-10-18 Impact factor: 13.506
Authors: Solveig Hofvind; Per Skaane; Joann G Elmore; Sofie Sebuødegård; Solveig Roth Hoff; Christoph I Lee Journal: Radiology Date: 2014-04-01 Impact factor: 11.105
Authors: Anna M Chiarelli; Kristina M Blackmore; Lucia Mirea; Susan J Done; Vicky Majpruz; Ashini Weerasinghe; Linda Rabeneck; Derek Muradali Journal: J Natl Cancer Inst Date: 2020-04-01 Impact factor: 13.506
Authors: Deirdre A Hill; Jennifer S Haas; Robert Wellman; Rebecca A Hubbard; Christoph I Lee; Jennifer Alford-Teaster; Karen J Wernli; Louise M Henderson; Natasha K Stout; Anna N A Tosteson; Karla Kerlikowske; Tracy Onega Journal: J Gen Intern Med Date: 2017-12-06 Impact factor: 5.128
Authors: Laura J Esserman; Ian M Thompson; Brian Reid; Peter Nelson; David F Ransohoff; H Gilbert Welch; Shelley Hwang; Donald A Berry; Kenneth W Kinzler; William C Black; Mina Bissell; Howard Parnes; Sudhir Srivastava Journal: Lancet Oncol Date: 2014-05 Impact factor: 41.316